Chemoprevention of prostate cancer: an updated view (Q37975188)

26 August 2017

title

Chemoprevention of prostate cancer: an updated view (English)

1 reference

26 August 2017

1 reference

Eric A Klein

1

1 reference

26 August 2017

Ian M Thompson

series ordinal

2

1 reference

26 August 2017

publication date

12 January 2012

1 reference

26 August 2017

published in

World Journal of Urology

1 reference

26 August 2017

volume

30

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

189-194

1 reference

26 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Brief communication: The prevalence of high intake of vitamin E from the use of supplements among U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamin E supplementation and cataract: randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Vitamin E supplementation and macular degeneration: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Folic Acid for the Prevention of Colorectal Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Multifocal High Grade Prostatic Intraepithelial Neoplasia is a Risk Factor for Subsequent Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Active surveillance for prostate cancer: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

The cost of prostate cancer chemoprevention: a decision analysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Chemoprevention of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0822-9

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study

21 January 2018

1 reference

12 December 2020

Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.

1 reference

12 December 2020

Multi-drug resistant E.coli urosepsis in physicians following transrectal ultrasound guided prostate biopsies--three cases including one death.

1 reference

12 December 2020

Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial

1 reference

12 December 2020

Vitamin E supplementation and cardiovascular events in high-risk patients

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group

1 reference

12 December 2020

10.1007/S00345-011-0822-9

Identifiers

DOI

1 reference

26 August 2017

1 reference